Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.medicoremediesindia.com / www.medicoremediesindia.net / www.tabletandcapsules.com | |
Market Cap | 693.41 Cr. | |
Enterprise Value(EV) | 699.33 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.87 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 95.74 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 33.57 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 5.28 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 15.82 | Calculated using Price: 83.56 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 8.30 Cr. | 82,984,000 Shares |
FaceValue | 2 | |
About Medico Remedies Ltd. | ||
The company is engaged in manufacturing and selling of pharmaceutical formulation products in India. The company offers formulation pharmacy products including anti-infective, beta lactum, cephalosporin, antimalarial, antiretroviral, and anti-ulcer drugs, as well as antacids; vitamins, haematinics and other supplements and nonsteroidal anti-inflammatory drugs, antihistaminics, anti-diabetics, cardio vascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and creams and gels. |
1 Day |
|
+0.62% |
1 Week |
|
-1.17% |
1 Month |
|
-1.37% |
3 Month |
|
+14.62% |
6 Month |
|
+32.65% |
1 Year |
|
+328.79% |
2 Year |
|
+1196.92% |
5 Year |
|
+1627.46% |
10 Year |
|
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 9.23 | 7.14 | 7.97 | 10.47 | 5.67 | 5.72 | 5.61 | 8.31 | 14.02 | |
Return on Capital Employed (%) | 11.37 | 10.01 | 10.86 | 9.39 | 9.05 | 7.79 | 7.66 | 10.13 | 15.00 | |
Return on Assets (%) | 2.54 | 2.36 | 2.78 | 3.47 | 2.26 | 2.31 | 2.15 | 3.43 | 6.44 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
Shh. Funds | 9 | 14 | 15 | 16 | 27 | 28 | 30 | 32 | 37 | 44 | |
Non Curr. Liab. | 1 | 1 | 4 | 11 | 3 | 3 | 5 | 5 | 1 | 2 | |
Curr. Liab. | 22 | 22 | 26 | 21 | 30 | 45 | 40 | 38 | 38 | 42 | |
Minority Int. | |||||||||||
Equity & Liab. | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 76 | 87 | |
Non Curr. Assets | 8 | 10 | 9 | 10 | 14 | 17 | 19 | 17 | 18 | 23 | |
Curr. Assets | 23 | 26 | 37 | 38 | 46 | 59 | 57 | 58 | 59 | 65 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 76 | 87 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. TTM |
Net Sales | 45 | 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | 140 | |
Other Income | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | |
Total Income | 45 | 51 | 67 | 55 | 62 | 100 | 91 | 123 | 123 | 144 | |
Total Expenditure | -43 | -48 | -63 | -50 | -58 | -95 | -86 | -117 | -114 | -131 | |
PBIDT | 2 | 3 | 4 | 4 | 4 | 5 | 5 | 6 | 9 | 14 | |
Interest | -1 | -1 | -1 | -1 | -2 | -1 | -1 | -1 | -1 | -1 | |
Depreciation | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -3 | |
Taxation | 0 | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -2 | -3 | |
Exceptional Items | 0 | ||||||||||
PAT | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 7 | |
Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 2 | 3 | 0 | -4 | -3 | 5 | 5 | 1 | -11 | 2 | |
Cash Fr. Inv. | -2 | -4 | -2 | 0 | -3 | -5 | -4 | -3 | -17 | -3 | |
Cash Fr. Finan. | 0 | 2 | 3 | 2 | 6 | -1 | -1 | 3 | 18 | 7 | |
Net Change | 0 | 1 | 0 | -1 | 0 | -1 | 0 | 0 | -10 | 6 | |
Cash & Cash Eqvt | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | -10 | 6 |
Fri, 26 May 2023
Compliances-Reg.24(A)-Annual Secretarial Compliance Pursuant to Circular CIR/CFD/CMD1/27/2019 dated February 08 2019 for the purpose ofcompliance with Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements)Regulations 2015 please find enclosed herewith the Annual Secretarial Compliance Report forthe year ended 31st March 2023. |
Sat, 13 May 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication In compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements)Regulations 2015 please find enclosed the newspaper advertisements published in FinancialExpress (English Edition) and in Mumbai Lakshadeep (Marathi Edition) dated 13th May 2023 forPublication of announcement of Audited Financial Results for the quarter and year ended 31stMarch 2023. |
Sat, 13 May 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 please find enclosed herewith Press Release about "Medico Remedies Limited is pleased to announce its readiness to foray into ointment manufacturing segment. |
Fri, 09 Jun 2023 |
|
|
|
|
|